Tecentriq Disappoints In Post-Surgery Bladder Cancer
Fails To Hit Disease-Free Survival
Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
You may also be interested in...
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.
The King's College London spin-out has gained £11.5m backing to take its ‘parallel CAR-T’ into the clinic.